Why Is Karyopharm Therapeutics (NASDAQ:KPTI) Tumbling 22.25% Pre-Market on Tuesday?

Vinay Lochav

10 November 2026 11:43 PM AEDT

Why Is Karyopharm Therapeutics (NASDAQ:KPTI) Tumbling 22.25% Pre-Market on Tuesday?

Image Source: Shutterstock

You are reading a free article with opinions that may differ from the recommendation given by Kalkine in its paid research reports. Become a Kalkine member today to get access to our research reports, in-depth technical and fundamental research. Learn more

Start Your Free Trial Now!

Key Highlights

Karyopharm Therapeutics (NASDAQ:KPTI) is indicated at USD 0.0311 pre-market on November 10, 2026, which is 22.25% below a calculated prior close of USD 0.0400.
The company lodged Chapter 11 papers on November 2, 2026, supported by a USD 55 million Bankruptcy loan, with Ayrmid leading the bidding for a court-run sale expected to close in early 2027.
Nasdaq sent a delisting notice on November 4, 2026. Trading is suspended from November 11, 2026, and the ticker is expected to move to KPTIQ on an OTC market.
Under the proposed plan, common shareholders receive nothing, and the company expects its Equity to be worth nil following an 83% slide to USD 0.11 on November 2.

Key Drivers Behind the Karyopharm Pre-Market Fall (-22.25%)

Karyopharm Therapeutics, along with KPT Texas LLC, a subsidiary, lodged Chapter 11 petitions with the Southern District of Texas Bankruptcy Court, Houston Division, on November 2, 2026, alongside a prepackaged plan. Reports that day put the share price down 83% at USD 0.11, implying a Market Value near USD 2.5 million. Nasdaq issued a delisting notice on November 4, 2026 under Listing Rules 5101, 5110(b) and IM-5101-1, and the company has chosen not to appeal. Nasdaq trading halts at the opening bell on November 11, 2026, with OTC quotes under KPTIQ expected from that date onward. The USD 0.0311 pre-market price sits 22.25% beneath the calculated prior close of USD 0.0400 recorded on Monday, November 9. Under the plan, holders of common stock and of its 0% Series A Convertible Perpetual Preferred Stock get no payment.

Why It Matters: Bankruptcy Sale and Equity Write-Off

The driver is the bankruptcy process rather than any fresh news from Tuesday. Ayrmid, the parent of Gamida Cell, leads the bidding, no bid figure has been made public, and a court-supervised auction will proceed while the Business runs on a USD 55 million Loan from its existing lenders. Before the filing, Karyopharm faced USD 15.8 million of Debt coming due and had agreed a forbearance arrangement. Its 2025 figures showed roughly USD 115 million of net Xpovio sales, a loss near USD 196 million and an accumulated Deficit of USD 1.8 billion, while cash stood at USD 55 million at June 30, 2026. For broader context, when a firm says shareholders will be wiped out with nothing recovered, remaining stock often trades on speculation, forced sales by funds barred from holding Delisted names, and a rush to exit before suspension. These are broad patterns, not verified reasons for today's fall.

Pricing, Trading Depth and Downside for Karyopharm

Data published on October 22, 2026 listed 22.68 million shares, a 52-week price change of -91.51%, total debt of USD 328.53 million, cash of USD 65.11 million and short interest of 6.06 million shares, representing 26.70% of the total. At USD 0.0311 the market value is roughly USD 0.7 million (calculated), compared with an Enterprise value of USD 275.81 million on that earlier page. Bids and offers sit far apart at prices this low, a handful of trades can shift the quote, and a single tick changes the size of the move considerably. The main dangers are a complete loss for equity holders, trading halts, thin OTC Liquidity after November 11 and sharp rebounds. Nothing in this points to the decline continuing.

Where Things Stand

Karyopharm Therapeutics (NASDAQ:KPTI) is down 22.25% pre-market on November 10, 2026 because the company is under Chapter 11 protection, Nasdaq will suspend trading on November 11, 2026, and the plan expects common equity to be worth nothing. The USD 0.0311 quote signals that the market gives only a sliver of residual odds. Holders could see a zero recovery under the filed plan, alongside extreme volatility.

Download Free Report – Explore 3 Stock Ideas & Industry Insights

Unlock 3 stock ideas and key industry insights in our free report. This information is general in nature and does not consider your personal objectives, financial situation, or needs. It is not financial advice.

All investments involve risk—consider independent advice before making any investment decisions.

View 3 Research Reports

Disclaimer:

This article (“Article”) has been prepared by Kalkine Pty Limited (ABN 34 154 808 312) (Australian financial services licence number 425376) (“Kalkine”) and its related bodies corporate who are authorised to provide general financial product advice. Kalkine.com.au and its associated pages are published by Kalkine.

Any information/advice provided in this article is general in nature and does not take into account your objectives, financial situation or needs. You should therefore consider whether the information is appropriate for your objectives, financial situation and needs before acting upon it.

There may be a Product Disclosure Statement, Information Memorandum or other offer document (“Offer Document”) for the securities or other financial products referred to in Kalkine articles. You should obtain a copy of the Offer Document and consider it before making any decision about whether to acquire the security or financial product.

Kalkine strongly recommends that you seek advice from a financial adviser, stockbroker or other professional (including taxation and legal advice) before acting on any advice/information in this Article or on the Kalkine website. Not all investments are appropriate for all people.

The information in this Article and on Kalkine website has been prepared from a wide variety of sources, which Kalkine, to the best of its knowledge and belief, considers accurate. Kalkine has made every effort to ensure the reliability of the information contained in its articles (including this Article), newsletters and websites. All information represents our views at the date of publication and may change without notice.

The information in this Article does not constitute an offer to sell securities or other financial products or a solicitation of an offer to buy securities or other financial products.

Kalkine does not issue, sell or deal in any financial products.

This Article may contain information on past performance of particular investments. Please note past performance is neither an indicator nor a guarantee of future performance.

To the extent permitted by law, and excluding any dishonesty or gross negligence by Kalkine, Kalkine disclaims and excludes all liability for any direct, indirect, implied, punitive, special, incidental or other consequential loss or damage arising from the use of or reliance on this Article, the Kalkine website and any information published on the Kalkine website without any warranties or representations by Kalkine to you. To the extent the law prohibits or limits this exclusion, Kalkine limits its liability to the resupply of services.

Please also read our Terms & Conditions and Financial Services Guide for further information.

Employees and/or associates of Kalkine and its related entities may hold interests in the securities or other financial products covered in this Article or on the Kalkine website. Any such employees and associates are required to comply with certain safeguards, procedures and disclosures as required by law.

Some of the images/music that may be used in the Article are copyright to their respective owner(s). Kalkine does not claim ownership of any of the pictures displayed/music used in the Article unless stated otherwise. The images/music that may be used in the Article are taken from various sources on the internet, including paid subscriptions or are believed to be in public domain. We have used reasonable efforts to accredit the source wherever it was indicated or was found to be necessary.

Kalkine Media Pty Ltd, an affiliate of Kalkine Pty Ltd, may have received, or be entitled to receive, financial consideration in connection with providing information about certain entity(s) covered on its website.